Thursday, July 28, 2016 8:14:03 PM
Jul. 28, 2016 3:02 PM
Anavex 2-73 appears to have stopped the progression of Alzheimer's disease for 31 weeks.
The Anavex 2-73 data requires careful analysis.
A Phase 3 clinical trial is needed.
In a day in which the Anavex (NASDAQ:AVXL) team announced positive news regarding Anavex 2-73, the company's stock dropped 40 percent. How did that happen?
Some investors may have believed this drug was a cure for Alzheimer's disease and were disappointed by the results. There has been a strong and vocal short "interest" in the stock, but neither accounts for the stock's sharp drop.
Perhaps the most important reason for the sell-off of the stock is that some of Anavex's most vociferous opponents scared investors by interpreting the poster presentation as proof for their narrative that the drug is a scam. The assertion made by Adam Feuerstein, among others, is that patients are slowly and inexorably declining while on the drug (article). But that is not what the poster graphs show (poster presentation). There was no decline in patients taking Anavex alone; indeed for the group taking Anavex alone, there was a slight increase in MMSE scores (mini-mental state examination) and no change in ADCS-ADL scores. Rather than having an additive effect, donepezil (Aricept) over time seemed to reduce the effectiveness of Anavex. As an aside, the same was also found in the recent LMTX tau clinical trial suggesting as heretical as it may sound that the sigma-1 agonist Aricept may through NMDA receptor activation actually have a negative effect on some Alzheimer's patients over time. The key to Anavex is not likely as a sigma 1-agonist but as an inhibitor of the pathway that leads to oxidative stress (by inhibiting neuronal nitric oxide synthase) (image one), (image two).
The only other substance that has stopped the progression of Alzheimer's disease at six months is Korean red ginseng. And while the action of Anavex 2-73 and Korean red ginseng are similar but perhaps not exactly the same - the long-term possibilities of Anavex 2-73 can potentially be presaged by the results of Korean red ginseng.
Anavex 2-73 average MSME score baseline: 22
Anavex 2-73 average MSME score 31 weeks: 25
Korean red ginseng average MSME score baseline: 22
Korean red ginseng average MSME score 24 weeks: 26.5
Korean red ginseng average MSME score two years: 24
(Korean red ginseng trial, see especially Figure two).
Funding for a phase three clinical trial is needed to see if Anavex 2-73 holds up with more participants, over a longer period of time, and with a placebo. But as I always argue, the lack of a placebo, a large sample size and an extended study period do not prove results but it does not negate them either.
I don't invest in stocks, partly for what happened here where some investors appeared to be swayed by a misreading of the data. But I would neither be too elated as a short nor too discouraged as a long over the actual results.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM